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Schizophrenia: Symptoms & Pathologies
Computational Models of Mental Illness: 
Neurons, synapses and modulators
Example: Working Memory Model 
                                 
Pharmaceutical Industry: Progress & Projections
 
Other Projects...
In Silico Biosciences, Inc.  
Computational Neuropharmacology
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In Silico Biosciences, Inc.  
Symptoms of Schizophrenia
Positive Symptoms:  Delusions, 
hallucinations, thought disorders, 
movement disorders
Negative Symptoms: Blunted affect, 
difficulty initiating speech, lack of 
pleasure in life, decreased activity
Cognitive Symptoms: Working memory, 
attention, executive function, problem 
solving
Louis Wain1860-l939
William Kurelek, 1927–1977
— A spectrum of psychotic disorders characterized by distortions of reality  
withdrawal from social contact and disturbances of thought and language.
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Impact of Schizophrenia
Sham et al (1994) 
                         1% of the population worldwide has schizophrenia.
Schizophrenia is the 8th leading 
cause of disability worldwide among 
15-44 year-olds.
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Schizophrenia: Pathologies
(Javitt, 2004)
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Schizophrenia: Causes
Gottesman, 2003
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Computational Models of the Brain
Challenge: Construct a tractable model without making it 
too simple for an accurate simulation of mental disease.
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Do Mental Illnesses Have 
Predictable Dynamics?
(Gottschalk, 1995)
Elegant model & useful 
for treatment strategies, 
but difficult for developing 
new treatments.
(Huber, Braun, Krieg 1999)
Dynamics of Bipolar Disease
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Neuron doctrine: the nervous system 
is made up of discrete individual cells
Computational Models of the Brain
Friday, March 5, 2010
In Silico Biosciences, Inc.  
Computational Models of the Brain
Neurons are complicated capacitors
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Computational Models of the Brain
Voltage gated channels regulate polarization of neurons         
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Computational Models of the Brain
Hodgkin-Huxley Equation quantify membrane potential of neurons
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Synapses connect neurons.        
Computational Models of the Brain
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Presynaptic spike => transmitter release => postsynaptic potential change    
Computational Models of the Brain
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Receptor types: Ionotropic and Metabotropic  
Computational Models of the Brain
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Second messenger pathways
Computational Models of the Brain
Second messenger model:
Linear relation between receptor activation 
and effect based on experimental values of 
%-change.
Pathologies
(Greengard, 2001)
(Greengard, 2001)
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Pathologies of Schizophrenia
Some genes can be related to pathologies and suggest mechanisms of disease.    
(Meyer-Lindenberg, 2006)
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Dopamine Receptor Binding  
Predicts Antipsychotic Efficacy
PET scan of a 
schizophrenic brain. 
While patients 
performed a working 
memory task, the less 
the prefrontal cortex 
(red) activated, the more 
dopamine increased in 
the striatum (green).
Drugs that treat schizophrenia are “dirty”
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Drugs for Schizophrenia have 
Complicated Binding Kinetics
Receptor selectivity of various drugs for schizophrenia.
(Kapur, 2003)
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Receptor Activation Model: Differential equations simulating 
binding dynamics in a synaptic cleft        
Computational Models of the Brain
1. Estimate physiological presynaptic spike 
pattern.
2. Calculate diffusion from Stokes-Einstein 
equation and removal.
3. Calculate competitive binding on 
presynaptic receptors affecting release. 
4. Calculate competitive binding on 
postsynaptic receptors.
5. Calculate fraction of receptor activation.
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Connectivity determines function of the neural circuit         
Computational Models of the Brain
Implementation of normal 
And diseased state
P
P
BC BC
BS
OLM
OLM
Hippocampus
Model Output 
 Bits/sec information content
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Working Memory Model
Network dynamics -- Noisy potential well model
(Durstewitz, 2006)
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Working Memory Model
Connectivity & Neural Compartments
20 Pyramidal cells (10 stimulated)
10 Inhibitory interneurons
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Working Memory Model
Network dynamics -- Noisy potential well model
(Durstewitz, 2006)
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Working Memory Model
Stochastic working memory bursts       
Friday, March 5, 2010
In Silico Biosciences, Inc.  
Working Memory Model
Schizophrenia pathology         
D1-R activation: The prefrontal cortex is in a hypo-dopaminergic state 
(Davis, 1991), therefore the D1-R activation is reduced
NMDA-R function: There is a dysfunction in the NMDA-R associated with 
schizophrenia, therefore the NMDA-R maximum conductance is reduced.
GABA-R conductance: A dysfunction of GABA transporters in 
schizophrenia (Lewis, 2005) leads to an up-regulation of GABA-R 
receptors so that the GABA-R conductances is increased.
Background noise:  Patients with schizophrenia display a loss of signal 
to noise ration in brain function (Winterer, 2000), therefore the background 
noise is increased.
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Working Memory Model
Add receptors for drug actions.
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Working Memory Model
Process of tuning the working memory model
Step A: Calculate receptor 
activation from competition 
model for all receptors in the 
micro-circuit model in the 
presence of each drug dose.
Step B: Modify membrane 
currents due to drug action.
Step C: Run network model.
Step D: Recursively modify 
receptor effects to find best fit 
with clinical data.
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Working memory span results for various drug treatment for schizophrenia
and genetic variants of COMT.
In Silico Biosciences, Inc.  
Working Memory Model
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Working Memory Model
Correlation between ISB Working Memory model and clinical dataset
9 clinical interventions, 5 antipsychotics + COMT genotype
(Weickert 2003, Bertolino 2004)
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Developing Drugs
Build model that
shows strong
correlations
between existing
drugs and their
clinical outcome
Model
Clinical
Outcome
(1)
Consider wide range 
of receptor 
occupancies to 
determine which has 
best clinical 
outcome
(2)
Receptor
Occupancies
R1 R2 R3
Throw out
cases that
have bad
side effects
(3)
Side
Effect
EPS
Check with 
competition 
model that 
Ki’s lead to 
desired 
occupancies
(5)
Competition
Model
Determine
likely Ki’s
to develop
best drug
(4)
R1 R2 R3
Drug
Ki’s
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Pharmaceutical Industry
Number of discoveries have decreased as costs increase.
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Pharmaceutical Industry
(Kola, 2004)
Clinical Trials
Phase I: First in humans. Small group (20-100) of normals. 
Assess the safety, tolerability, pharmacokinetics.
Phase II: Larger groups of patients and controls.
Assess dose and efficacy.
Phase III: Large randomized controlled trials.
Assess effectiveness relative to "gold standard" treatment.
When do drugs fail in development?
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Limitations of Animal Models
34
Differences in drug metabolism
Different drug affinities
Absence of 
functional
genotypes
Incomplete
pathology in
transgenic mice
Different 
neurotransmitter
wiring
Placebo
response
Geerts, CNS Drugs 23,915
Friday, March 5, 2010
In Silico Biosciences, Inc.  
Computational Pharmacology
in the Drug Pipeline
Select multiple-receptor 
compounds.
Pre-screen compounds 
before clinical trials.
(pharmacokinetics)
Predict dose requirements 
in human subjects.
Experimental design 
for large trials.
Comparisons of 
marketed drugs.
Screen for possible 
side effects.
Screening 
by FDA.
(Entelos)
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• Midbrain (striatum) model to develop new polypharmacy drugs for schizophrenia 
validated with the PANSS (Positive and Negative Syndrome Scale).
In Silico Biosciences, Inc.  
Other projects...
Greater than three-fold improvement over the “gold standard” single-receptor prediction.
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The model output is a signal that is Fourier analyzed to extract the power in 
important brain wave frequency bands.
Changes in model output predicts changes in human EEG caused by drug therapy.
Other Projects...
Pharmaco-EEG model simulates brain waves generated
by a network of neurons in the human cortex
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Pharmaco-EEG module simulates brain waves generated
by a network of neurons in the human cortex
Each of the 120 model neurons in the network contains the biophysical details of membrane currents,
synaptic connections and drug actions. Oscillations emerge from the network activity to simulate changes
in brain waves caused by drug effects.
Other Projects...
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• Extra-pyramidal symptom model is re-purposed as a Parkinsonʼs disease symptom 
model to screen orphaned drugs for new therapy (M.J. Fox Foundation).
• Develop treatments for cognitive impairment in Alzheimerʼs disease.
• Virtual clinical trials for drug effectiveness on genetic variants.
In Silico Biosciences, Inc.  
Other projects...
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Schizophrenia
“Schizophrenia” was coined by Eugen Bleuler (1908) to mean a 
“splitting of the mind” to describe the separation of function between 
personality, thinking, memory, and perception.
— A spectrum of psychotic disorders characterized by distortions of reality and 
disturbances of thought and language and withdrawal from social contact.
“Schizophrenia is a disease of language and logic.” - David Lewis (2009)
Dementia praecox (“premature dementia”) refers to a chronic, 
deteriorating disruption in cognitive or mental functioning such as in 
attention, memory, and goal-directed behavior. -  Emil Kraepelin (1896).
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Development of pharmaceutical therapy
for Schizophrenia
1948: Pierre Huguenard used 
promethazine to induce 
relaxation and indifference in 
surgical patients.
1947: Synthesized promethazine with sedative and 
antihistaminic effects.
Henri Laborit, believed the 
compound caused 'artificial 
hibernation', or "chemical 
lobotomy"
1952: Jean Delay and Pierre Deniker, First clinical trial on 38 psychotic 
patients with chlorpromazine. Improvements in thinking and emotional 
behaviour.
By 1954, chlorpromazine (Thorazine) was being used in the United 
States to treat schizophrenia.
1959: Paul Janssen, “finding a treatment for amphetamine intoxication 
would provide a cure for paranoid schizophrenia”.
Haloperidol reversed amphetamine intoxication in mice.
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